Table 4 Pathological complete response (pCR), overall survival (OS) and disease free survival rates (DFS) rates among the different subtypes overall and in subgroups.
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
Intrinsic subtype on pre-chemotherapy biopsies | Pathologic complete response (pCR) | pCR rates in % | Overall survival (%) | Disease free survival (%) | p value |
|---|---|---|---|---|---|
Luminal A | pCR (n = 4) | 5.3 | 100 | 100 | 0.426 (OS) |
no pCR (n = 71) | 87.3 | 71.8 | 0.243 (DFS) | ||
Luminal B HER2+ | pCR (n = 25) | 35.2 | 100 | 100 | 0.22 (OS) |
no pCR (n = 46) | 89.1 | 71.7 | 0.037 (DFS) | ||
NA (n = 1) | |||||
Luminal B HER2− | pCR (n = 6) | 13.6 | 83.3 | 66.6 | 0.51 (OS) |
no pCR (n = 38) | 57.9 | 44.7 | 0.85 (DFS) | ||
HER2+ | pCR (n = 26) | 43.3 | 100 | 88.5 | 0.03 (OS) |
no pCR (n = 34) | 82.3 | 44.1 | 0.03 (DFS) | ||
Triple negative | pCR (n = 42) | 47.2 | 95.2 | 92.3 | < 0.001 (OS) |
no pCR (n = 47) | 63.8 | 51.1 | < 0.001 (DFS) | ||
NA (n = 1) |
